Literature DB >> 18353629

Making progress against cancer in Europe in 2008.

Tit Albreht1, Martin McKee, Delia-Marina Alexe, Michel P Coleman, Jose M Martin-Moreno.   

Abstract

Europe is facing a cancer epidemic, with rapidly increasing incidence rates. Population growth and ageing will further increase the annual number of new patients with cancer. Cancer is a huge and growing contributor to the burden of disease and premature death within the European Union (EU). One in four of all deaths in the EU is attributable to cancer, and in the age range 45-64 years, the figure is almost one in two deaths. The 27 EU Member States differ greatly in cancer incidence, mortality and survival. Yet at least one-third of the cancer burden is preventable and a further third can be detected early and treated effectively, even on the basis of existing knowledge. "Cancer", however, comprises an extremely complex group of diseases and achieving the full potential for prevention and treatment poses very significant challenges. Success in cancer control will depend on a co-ordinated approach that involves every aspect of policy and service delivery. The objective of this paper is to outline the basic requirements of an integrated strategy for cancer control, emphasising the co-ordination of the key elements of primary prevention, secondary prevention (screening), integrated care and advances in research, all at national and EU level. It is based on a detailed review of the status of cancer control in the EU today and summarises the policy recommendations arising from this review, undertaken under the auspices of the Slovenian Presidency of the European Union in 2008.

Entities:  

Mesh:

Year:  2008        PMID: 18353629     DOI: 10.1016/j.ejca.2008.02.015

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  14 in total

1.  Theranostic applications: Non-ionizing cellular and molecular imaging through innovative nanosystems for early diagnosis and therapy.

Authors:  Sergio Casciaro
Journal:  World J Radiol       Date:  2011-10-28

2.  The white book of radiation oncology in Spain.

Authors:  Ismael Herruzo; Jesús Romero; Amalia Palacios; Ana Mañas; Pilar Samper; Eloísa Bayo; Ferran Guedea
Journal:  Clin Transl Oncol       Date:  2011-06       Impact factor: 3.405

3.  Assessing predicted age-specific breast cancer mortality rates in 27 European countries by 2020.

Authors:  R Clèries; R M Rooney; M Vilardell; J A Espinàs; T Dyba; J M Borras
Journal:  Clin Transl Oncol       Date:  2017-07-19       Impact factor: 3.405

4.  Hypoxia reduces the efficiency of elisidepsin by inhibiting hydroxylation and altering the structure of lipid rafts.

Authors:  Anna Király; Tímea Váradi; Tímea Hajdu; Ralph Rühl; Carlos M Galmarini; János Szöllősi; Peter Nagy
Journal:  Mar Drugs       Date:  2013-12-02       Impact factor: 5.118

5.  N-(5-Mercapto-1,3,4-Thiadiazol-2-yl)-2-Phenylacetamide Derivatives: Synthesis and In-vitro Cytotoxicity Evaluation as Potential Anticancer Agents.

Authors:  Ahmad Mohammadi-Farani; Neda Heidarian; Alireza Aliabadi
Journal:  Iran J Pharm Res       Date:  2014       Impact factor: 1.696

6.  Expression and function of bcl-2 proteins in melanoma.

Authors:  Jürgen Eberle; Amir M Hossini
Journal:  Curr Genomics       Date:  2008-09       Impact factor: 2.236

7.  Use of general practice, diagnostic investigations and hospital services before and after cancer diagnosis - a population-based nationwide registry study of 127,000 incident adult cancer patients.

Authors:  Karina Garnier Christensen; Morten Fenger-Grøn; Kaare Rud Flarup; Peter Vedsted
Journal:  BMC Health Serv Res       Date:  2012-07-28       Impact factor: 2.655

8.  Study protocol of a randomized controlled trial to improve cancer prevention behaviors in adolescents and adults using a web-based intervention supplemented with SMS.

Authors:  Alberto Lana; Maria Olivo del Valle; Santiago López; Goretti Faya-Ornia; Maria Luisa López
Journal:  BMC Public Health       Date:  2013-04-17       Impact factor: 3.295

9.  Incidence and Mortality Rate of Common Gastrointestinal Cancers in South of Iran, a Population Based Study.

Authors:  J Hassanzade; H Molavi E Vardanjani; M Farahmand; A R Rajaiifard
Journal:  Iran J Cancer Prev       Date:  2011

10.  Synthesis and In-vitro Cytotoxicity Assessment of N-(5-(Benzylthio)-1,3,4- thiadiazol-2-yl)-2-(4-(trifluoromethyl)phenyl)acetamide with Potential Anticancer Activity.

Authors:  Alireza Aliabadi; Zaman Hasanvand; Amir Kiani; Seyed Saber Mirabdali
Journal:  Iran J Pharm Res       Date:  2013       Impact factor: 1.696

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.